New approaches to molecular cancer therapeutics

被引：300

作者：

Collins, Ian ^{[1
]}

Workman, Paul ^{[1
]}

机构：

[1] Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England

来源：

NATURE CHEMICAL BIOLOGY | 2006年 / 2卷 / 12期

关键词：

D O I：

10.1038/nchembio840

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer drug development is leading the way in exploiting molecular biological and genetic information to develop 'personalized' medicine. The new paradigm is to develop agents that target the precise molecular pathology driving the progression of individual cancers. Drug developers have benefited from decades of academic cancer research and from investment in genomics, genetics and automation; their success is exemplified by high-profile drugs such as Herceptin ( trastuzumab), Gleevec ( imatinib), Tarceva (erlotinib) and Avastin (bevacizumab). However, only 5% of cancer drugs entering clinical trials reach marketing approval. Cancer remains a high unmet medical need, and many potential cancer targets remain undrugged. In this review we assess the status of the discovery and development of small-molecule cancer therapeutics. We show how chemical biology approaches offer techniques for interconnecting elements of the traditional linear progression from gene to drug, thereby providing a basis for increasing speed and success in cancer drug discovery.

引用

页码：689 / 700

页数：12

共 132 条

[11] Systematic discovery of multicomponent therapeutics [J].

Borisy, AA ;

Elliott, PJ ;

Hurst, NW ;

Lee, MS ;

Lehár, J ;

Price, ER ;

Serbedzija, G ;

Zimmermann, GR ;

Foley, MA ;

Stockwell, BR ;

Keith, CT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) :7977-7982

[12]

Brehmer D, 2005, CANCER RES, V65, P379

[13] An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors [J].

Brummelkamp, TR ;

Fabius, AWM ;

Mullenders, J ;

Madiredjo, M ;

Velds, A ;

Kerkhoven, RM ;

Bernards, R ;

Beijersbergen, RL .

NATURE CHEMICAL BIOLOGY, 2006, 2 (04) :202-206

[14] Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].

Capdeville, R ;

Buchdunger, E ;

Zimmermann, J ;

Matter, A .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502

[15] A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design [J].

Card, GL ;

Blasdel, L ;

England, BP ;

Zhang, C ;

Suzuki, Y ;

Gillette, S ;

Fong, D ;

Ibrahim, PN ;

Artis, DR ;

Bollag, G ;

Milburn, MV ;

Kim, SH ;

Schlessinger, J ;

Zhang, KYJ .

NATURE BIOTECHNOLOGY, 2005, 23 (02) :201-207

[16] Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation [J].

Chatterjee-Kishore, M ;

Miller, CP .

DRUG DISCOVERY TODAY, 2005, 10 (22) :1559-1565

[17] The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors [J].

Cheung, KMJ ;

Matthews, TP ;

James, K ;

Rowlands, MG ;

Boxall, KJ ;

Sharp, SY ;

Maloney, A ;

Roe, SM ;

Prodromou, C ;

Pearl, LH ;

Aherne, GW ;

McDonald, E ;

Workman, P .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (14) :3338-3343

[18] A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells [J].

Chiosis, G ;

Timaul, MN ;

Lucas, B ;

Munster, PN ;

Zheng, FF ;

Sepp-Lorenzino, L ;

Rosen, N .

CHEMISTRY & BIOLOGY, 2001, 8 (03) :289-299

[19] Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP [J].

Choi, JW ;

Chen, J ;

Schreiber, SL ;

Clardy, J .

SCIENCE, 1996, 273 (5272) :239-242

[20] Lessons from natural molecules [J].

Clardy, J ;

Walsh, C .

NATURE, 2004, 432 (7019) :829-837

← 1 2 3 4 5 6 7 8 9 10 →